Quince Therapeutics, Inc.
QNCXOther · Non-accelerated filer<br>Smaller reporting company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$58.1M | −$57.3M | −$34.6M | −$52.0M | −$90.3M | −$78.9M |
| Net income | −$84.0M | −$56.8M | −$31.4M | −$51.7M | −$89.9M | −$76.8M |
| Total assets | $93.5M | $114.5M | $167.9M | $103.9M | $133.2M | $189.5M |
| Total liabilities | $129.2M | $84.3M | $82.8M | $3.3M | $14.6M | $17.2M |
| Equity | −$35.7M | $30.1M | $85.1M | $100.6M | $118.6M | $172.3M |
| EPS (diluted) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 | — |
| Shares out. | 44.0M | 43.2M | 36.3M | 30.1M | 29.6M | 29.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 235.1%
- Return on assets
- −89.8%
- Return on capital (ROCE)
- −115.5%
- Liabilities / assets
- 138.2%
- Debt / equity
- —
- Book value / share
- $-0.81
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -21.94distress
- Accruals / assets
- −45.5%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Benatti LucaDirector | Dec 26, 2025 | Sell | 50,000 | $3.47 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.8M | 2.3 | -1.5% |
| Apr 30, 2026 | 1.8M | 1.1 | -8.6% |
| Apr 15, 2026 | 2.0M | 1.0 | -85.9% |
| Mar 31, 2026 | 13.8M | 1.0 | +24.0% |
| Mar 13, 2026 | 11.2M | 1.0 | +34.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 21, 2026
- Entered a material agreement · Completed an acquisition or disposition · Unregistered equity sale · Director / officer change · Amended charter or bylaws · Regulation FD disclosureMay 18, 2026
- Other material eventApr 28, 2026
- Director / officer changeApr 22, 2026
- Modified shareholder rights · Amended charter or bylawsApr 9, 2026
- Terminated a material agreement · Regulation FD disclosureMar 30, 2026
- Delisting / listing-standard noticeMar 20, 2026
- Results of operations · Other material eventFeb 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.